Last reviewed · How we verify
NCT06846411: EMPA-FIT
The EMPA-FIT Study
Phase 4 trial testing Empagliflozin 10 mg in Diabetes in 46 participants. Currently enrolling.
30 September 2025
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 1 January 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Empagliflozin 10 mg — full drug profile →
- Metformin (metformin) — full drug profile →
Conditions studied
- Diabetes — all drugs for Diabetes →
- Diabetes Mellitus, Type II — all drugs for Diabetes Mellitus, Type II →
Sponsor
Seoul National University Bundang Hospital
Who can join
20 and older, any sex, with Diabetes or Diabetes Mellitus, Type II. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multicenter, open-label, prospective study randomized 46 drug-naïve adults with T2D (HbA1c 6.5%-10.0%) to receive empagliflozin (10 mg/day) or metformin (1,000 mg/day) for 12 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06846411
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Empagliflozin 10 mg
Trials testing the same drug.
- NCT06674109 — SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial · Phase 4 · not yet recruiting
- NCT06818305 — Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in · Phase 2 · terminated
- NCT05905965 — Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment · Phase 3 · recruiting
- NCT06632561 — Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus · Phase 4 · completed
- NCT03087773 — Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction · Phase 3 · completed
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06846411 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 26 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06846411.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing